Samsung Biologics’s makes tender offer to acquire PolyPeptide: the advisord
Samsung Biologics made recommended tender offer to acquire PolyPeptide at a price of CHF 44.31 per share. The tender offer values PolyPeptide’s equity at approximately CHF 1.46 billion.
In connection with the deal, Lenz & Staehelin advised PolyPeptide’s largest shareholder, Draupnir Holding, while Homburger advised PolyPeptide Group.
The parties
Samsung Biologics is a Korean Contract Development and Manufacturing Organization (CDMO).
Listed on SIX Swiss Exchange, PolyPeptide Group is a Swiss-based specialized CDMO for peptide-based active pharmaceutical ingredients.
The Lenz & Stahelin team
Lenz & Staehelin’s team consisted in Jacques Iffland, Ariel Ben Hattar, Ilya Skurikhin and Ottavia Cabrini.
The Homburger team
The Homburger team is led by Frank Gerhard and included Micha Fankhauser, Nicola Togni, Patrick Schmidt, Matthias Müller, Pepe Hünerwadel, Matteo Gasser, and Filippo Moggi (all corporate / M&A, capital markets), Richard Stäuber, Allegra Arnold, and Anna-Katharina Leitz (all competition), as well as Stefan Oesterhelt (tax).
